Rapid Ebola Virus Detection Assay Evaluated
|
By LabMedica International staff writers Posted on 17 Nov 2015 |

Image: The Diagnostics-in-a-Suitcase used to screen for Ebolavirus disease (Photo courtesy of Institut Pasteur, Dakar).
Ebolavirus (EBOV) infection is mainly diagnosed by various in-house and commercial real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays used in up to 38 laboratories implemented at or close to Ebola treatment centers (ETC) in West Africa.
Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.
An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.
The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.
The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.
Related Links:
Institut Pasteur de Dakar
Qiagen
Cepheid
Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.
An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.
The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.
The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.
Related Links:
Institut Pasteur de Dakar
Qiagen
Cepheid
Latest Microbiology News
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







